Gaborone CRS
Welcome,         Profile    Billing    Logout  
 26 Trials 
42 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martinez, Maria C
NCT03811509: Breast Cancer Women on Aromatase Inhibitors Treatment

Recruiting
4
1000
Europe
bisphosphonate, denosumab
Parc de Salut Mar, Instituto de Salud Carlos III
Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized
01/21
12/22
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
NCT04941300: ColoRectal Cancer Screening for Southern California Community Health Centers

Completed
3
55999
US
Mailed FIT Outreach, Standardized navigation
University of California, San Diego, National Cancer Institute (NCI)
Colorectal Cancer
08/24
08/24
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruiting
3
310
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
11/24
08/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NAPOLI-2, NCT04005339: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Recruiting
2
50
US
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Georgetown University, Ipsen
Advanced Biliary Tract Cancer
04/25
12/25
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Recruiting
2
48
US, RoW
Selgantolimod, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
11/26
05/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Not yet recruiting
1
30
US
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI)
HIV-1
10/26
08/27
TEFA, NCT02605148: Family Prevention: Glutenfree Diet to Preserve Beta-cell Function

Active, not recruiting
N/A
60
Europe
Gluten free diet, Omega 3 fatty acid, Vitamin D, Probiotics
Lund University, Juvenile Diabetes Research Foundation
Prediabetes, Type 1 Diabetes
12/22
12/22
mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn
N/A
30
Europe
No Intervention
Takeda
Metachromatic Leukodystrophy (MLD)
07/24
07/24
NCT06573723: Institutional Registry of Rare Diseases

Recruiting
N/A
380
RoW
Hospital Italiano de Buenos Aires
Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, Cushing Syndrome
12/34
12/34
NCT02512250: Swiss Hemophilia Registry

Recruiting
N/A
900
Europe
Registry
Swiss Hemophilia Network
Hemophilia and Other Severe Bleeding Disorders
12/25
12/25
Suryavanshi, Nishi
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05383742: Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Recruiting
2
330
RoW
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
12/27
05/28
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
NCT04518228: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting
N/A
325
US, RoW
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme LLC
HIV Infections, Tuberculosis
03/26
03/26
Kakhu, Tebogo J
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
Chakalisa, Unoda A
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Active, not recruiting
1/2
168
US, RoW
Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART)
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
02/23
06/25
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
NCT04518228: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting
N/A
325
US, RoW
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme LLC
HIV Infections, Tuberculosis
03/26
03/26
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Takuva, Simba
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Martinez, Maria C
NCT03811509: Breast Cancer Women on Aromatase Inhibitors Treatment

Recruiting
4
1000
Europe
bisphosphonate, denosumab
Parc de Salut Mar, Instituto de Salud Carlos III
Osteoporosis, Osteoporosis Fracture, Arthralgia Generalized
01/21
12/22
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
NCT04941300: ColoRectal Cancer Screening for Southern California Community Health Centers

Completed
3
55999
US
Mailed FIT Outreach, Standardized navigation
University of California, San Diego, National Cancer Institute (NCI)
Colorectal Cancer
08/24
08/24
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruiting
3
310
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
11/24
08/26
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
NAPOLI-2, NCT04005339: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

Recruiting
2
50
US
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Georgetown University, Ipsen
Advanced Biliary Tract Cancer
04/25
12/25
NCT05551273: Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Recruiting
2
48
US, RoW
Selgantolimod, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV Infections
11/26
05/27
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Terminated
2
44
US
Letermovir Oral Tablet, Prevymis
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, Teropavimab, GS-2872, 10-1074-LS, Zinlirvimab, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/28
08/29
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Not yet recruiting
1
30
US
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI)
HIV-1
10/26
08/27
TEFA, NCT02605148: Family Prevention: Glutenfree Diet to Preserve Beta-cell Function

Active, not recruiting
N/A
60
Europe
Gluten free diet, Omega 3 fatty acid, Vitamin D, Probiotics
Lund University, Juvenile Diabetes Research Foundation
Prediabetes, Type 1 Diabetes
12/22
12/22
mECHromatic, NCT05755568: A Study to Learn About Metachromatic Leukodystrophy (MLD) in Children in Spain

Withdrawn
N/A
30
Europe
No Intervention
Takeda
Metachromatic Leukodystrophy (MLD)
07/24
07/24
NCT06573723: Institutional Registry of Rare Diseases

Recruiting
N/A
380
RoW
Hospital Italiano de Buenos Aires
Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis, Pheochromocytoma, Paraganglioma, Von Hippel-Lindau Disease, Immunoglobulin G4-Related Disease, Demyelinating Diseases, Inborn Errors of Metabolism, Eosinophilic Gastrointestinal Disorders, Hypertrophic Cardiomyopathy, Gaucher Disease, Congenital Adrenal Hyperplasia, Hereditary Angioedema, Pulmonary Hypertension, Wilson Disease, Vascular Anomalies, Mastocytosis, Multiple Endocrine Neoplasia, Inflammatory Bowel Diseases, Prader-Willi Syndrome, Hirschsprung Disease, Cushing Syndrome
12/34
12/34
NCT02512250: Swiss Hemophilia Registry

Recruiting
N/A
900
Europe
Registry
Swiss Hemophilia Network
Hemophilia and Other Severe Bleeding Disorders
12/25
12/25
Suryavanshi, Nishi
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT04311502: Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Completed
2
104
RoW
Clofazimine (CFZ), Rifapentine (RPT), Isoniazid (INH), Pyrazinamide (PZA), Ethambutol (EMB), Rifampicin (RIF), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
06/24
06/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
NCT05383742: Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Recruiting
2
330
RoW
Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD), Pyrazinamide (PZA), ethambutol (EMB), Rifampicin, Isoniazid
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculous Meningitis
12/27
05/28
NCT02906007: Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Active, not recruiting
1/2
54
RoW
Bedaquiline, BDQ
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV
02/24
08/25
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
NCT04518228: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting
N/A
325
US, RoW
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme LLC
HIV Infections, Tuberculosis
03/26
03/26
Kakhu, Tebogo J
PHOENIx MDR-TB, NCT03568383: Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Recruiting
3
5610
RoW
Delamanid (DLM), Isoniazid (INH), Pyridoxine (vitamin B6)
National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, MDR
07/27
07/27
NCT05007821: Linezolid Dosing Strategies in Drug-Resistant TB

Active, not recruiting
2
138
RoW
Linezolid 600 mg, LZD, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW), Bedaquiline 200 mg, BDQ, Bedaquiline 100 mg, Delamanid 300 mg, DLM, Clofazimine 300 mg, CFZ, Clofazimine 100 mg
National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
08/25
03/26
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
Chakalisa, Unoda A
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
RAD-TB, NCT06192160: Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
2
315
RoW
Isoniazid, INH, Rifampicin, RIF, Pyrazinamide, PZA, Ethambutol, EMB, Bedaquiline, BDQ, Pretomanid, Pa, Linezolid, LZD, TBI-223, Sutezolid, SZD
National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance
Pulmonary Tuberculosis
03/26
03/27
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
MOCHA, NCT03497676: More Options for Children and Adolescents (): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Active, not recruiting
1/2
168
US, RoW
Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Edurant, Long-Acting Injectable Cabotegravir (CAB LA), Long-Acting Injectable Rilpivirine (RPV LA), Combination Antiretroviral Therapy (cART)
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
02/23
06/25
NCT03141060: Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Active, not recruiting
1/2
37
RoW
Delamanid, DLM, Optimized multidrug background regimen (OBR) for children with MDR-TB
National Institute of Allergy and Infectious Diseases (NIAID), Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis, HIV Infections
05/25
07/26
NCT04518228: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Recruiting
N/A
325
US, RoW
Bictegravir (BIC), Tenofovir alafenamide (TAF), Cabotegravir (CAB), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
National Institute of Allergy and Infectious Diseases (NIAID), International Maternal Pediatric Adolescent AIDS Clinical Trials Group, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Gilead Sciences, ViiV Healthcare, Merck Sharp & Dohme LLC
HIV Infections, Tuberculosis
03/26
03/26
Leader, CRS
HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

Completed
1
38
RoW
CH505TF gp120, GLA-SE adjuvant, Placebo
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
07/24
07/24
CoVPN3008TB, NCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Recruiting
N/A
6000
RoW
Clinical Evaluation at Day 4, Laboratory Evaluation at Day 4, Clinical Evaluation at week 26, Laboratory Evaluation at week 26
COVID-19 Prevention Network, National Institute of Allergy and Infectious Diseases (NIAID), Medical Research Council, South Africa
Tuberculosis
10/25
10/25
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25
Takuva, Simba
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study

Active, not recruiting
N/A
13
RoW
Analytical Treatment Interruption
HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infection
02/25
02/25

Download Options